Mr. Bar-Nir joined Kamedis in August 2015 as CEO.
He has extensive experience in leading companies through the transition from small to large scale business. Prior to joining Kamedis, Mr. Bar-Nir served as the CEO of Pollogen, an innovative company in development, marketing and sales of invasive and non-invasive aesthetic medical devices and Skin care products. Previously, Mr. Bar-Nir was CEO of CogniFit, a software company that specializes in programs that assess and train cognitive abilities and B-Plan, a company that develops business planning tools. He has extensive international sales and marketing experience as well as a technical and operational background Mr. Bar-Nir earned his BA, Economics and Business Administration from the University of Haifa.
Mr. Alon Netser, CFO
Mr. Alon Netser joined Kamedis in June 2017 as CFO. Mr. Netser have more than 12 years of global financial experience in leading strategy and business development, commercialization, E-commerce, Product Supply and financial forecasting, portfolio management, and financial analysis.
Prior joining Kamedis, Mr. Netser worked for P&G in several financials roles, in KPMG as a consultant and was a pilot in the Israeli Air force.
Mr. Netser holds a BA in Accounting and Economics and an International Executive MBA from Kellogg-Recanati program, both from Tel Aviv University.
Ms. Iris Bincovich, VP Sales & Marketing
Ms. Bincovich joined Kamedis in October 2015 as VP Sales and Marketing.
She has a vast experience as International Sales & Marketing & Business Development as well as a valuable expertise in developing global business strategies, achieving maximum potential. In addition her experience includes opening and penetrating new markets, establishing international marketing and distribution infrastructures, identifying and dealing with opportunities.
She brings proven record of hundreds of successful international transactions from management positions in Chemicals, Consumer Goods, Medical Device, Dermal applications and Cosmetics. Moreover she accompanied startup companies from early stage to commercialization.
She holds a B.Sc in Chemistry from Technion - Israel Institute of Technology.
Dr. Yonit Bomstein, Ph.D., MBA, CTO and Head of R&D
Dr. Yonit Bomstein joined Kamedis in 2010, bringing extensive practical and managerial experience in the biopharmaceutical industry, clinical research, biotechnological and pharmaceutical discovery and development, business development, and operational strategic management.
Dr. Bomstein served as CEO at a clinical-stage biotech company developing an immunomodulating treatment for Premenstrual Syndrome. She previously held a position as VP R&D leading a preclinical program for an anti-melanoma immunotherapeutic drug at a biotechnology company GammaCan. Prior thereto Dr. Bomstein led a preclinical project supporting clinical trials under FDA at a biopharmaceutical company Proneuron Biotechnologies that is being developed autologous immune cell therapy for severe spinal-cord injuries.
Dr. Bomstein holds a Ph.D. in Immunology from the Weizmann Institute of Science, and an MBA from Tel-Aviv University.
Dr. Deganit Barak-Shinar, Ph.D., VP Clinical, Regulation and QA
Leading the clinical and regulatory activities at Kamedis, Dr. Deganit Barak-Shinar manages clinical research and trials, regulation, FDA and CE submissions, and collaboration with physicians and clinicians worldwide.
With over 10 years of experience in the bio-medical industry, Dr. Barak-Shinar held, prior to Kamedis, executive positions at several bio-medical companies in the fields of cardiology, sleep medicine and gynecology. Her broad experience includes also business development, strategic marketing, and clinical- research and trials.
She holds a Ph.D. in Bio-Medical Engineering from Tel-Aviv University, and her research and published papers focused on advanced models of non-invasive medical sensors. She holds an M.Sc. from Tel Aviv University and a B.Sc. from the Technion - Israel Institute of Technology (both Magna Cum Laude).
Mr. Udi Peretz, VP Operations
Udi Peretz has gained 25 years of management and production experience in such industries as biotech, pharmaceuticals and chemicals, including in the management of a plant-extraction production facility in China.
In addition to his position as VP operations at Kamedis, Udi also serves as CEO at Green Mountain Biotech, a subsidiary of Kamedis. He earned his B.Sc. in Agriculture and his M.Sc. in Phytopathology and Microbiology from the Hebrew University of Jerusalem.